Sangamo Therapeutics surges after crossing above key SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 03 2025
0mins
Source: Benzinga
Sangamo Therapeutics Inc. saw a significant price increase of 51.33% as it crossed above its 5-day SMA, indicating strong investor interest.
The surge in Sangamo's stock price comes amid positive developments in its clinical trials for the gene therapy product, which has shown promising results in early phases. Investors are optimistic about the potential for future approvals and market entry, driving demand for the stock.
This substantial rise reflects growing confidence in Sangamo's pipeline and the overall interest in gene therapy solutions, positioning the company favorably in the biotech sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
